DanCann Pharma A/S' Pre-Validation Batches Meets European Standards, paving the Path for Final Product Approval

COPENHAGEN, Denmark, 01 June 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish biopharmaceutical company powered by cannabinoids, is pleased to announce the successful QC analysis of its pre-validation batches. The Company has confirmed that all batches have been tested in accordance with European (German and Danish) standards, meeting the required specifications and further advancing the approval process.

As part of its commitment to ensuring the highest standards of quality and compliance, DanCann Pharma conducted comprehensive testing of its pre-validation batches. The testing process followed European (German and Danish) standards, which encompass stringent requirements and guidelines for the assessment of cannabinoid-based products.

The results of the analysis have demonstrated that all pre-validation batches have successfully met the rigorous specifications set by European (German and Danish) standards. This achievement underscores DanCann Pharma's unwavering dedication to producing safe and effective therapeutic cannabinoids in line with the highest regulatory and industry requirements.

"We are delighted to announce that our pre-validation batches have been tested in accordance with European (German and Danish) standards, meeting the necessary specifications. This milestone reflects the exceptional expertise and commitment of our team, and reinforces our commitment to delivering industry leading cannabinoid-based products to patients in need," said Morten Martinsen, Head of Business Development of DanCann Pharma.

The successful analysis of the pre-validation batches brings DanCann Pharma one step closer to obtaining final approval from the Danish Medicines Agency for the release of its products. With the Company remaining on track with its timeline, it is well-positioned to proceed with the next phase of the product approval process.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company.

The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma is EU-GMP-approved by the Danish Medicines Agency under the Danish Pilot Programme for medical cannabis, and have, among other things, license for manufacturing, export, import and distribution. The DanCann Pharma group also owns the subsidiary CannGros ApS, which is the market leader in Denmark with the import and distribution of the products Bedrocan®, Bedica® and Bediol® to all the Danish pharmacies.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm and side listed on OTCQB Venture Market in USA (OTCQB: DCPXF).

For more information, visit: www.dancann.com  

For further information, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: [email protected]

Website: www.dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.